硫代bFGF寡核苷酸抑制HepG2和Hep2细胞的增殖

目的探讨硫代修饰对bFGF寡核苷酸抑制HepG2和Hep2细胞增殖的影响。方法设计、合成bFGF寡核苷酸,聚乙烯亚胺(jetPEI)介导其转染入HepG2和Hep2细胞,荧光显微镜观察其在细胞中的定位,流式细胞仪分析转染效率,MTT法检测细胞增殖。结果bFGF反/正义硫代寡核苷酸被jetPEI介导高效转染入细胞内,主要位于细胞核。反/正义硫代寡核苷酸均呈剂量时间依赖地抑制细胞增殖,相同剂量时正硫代寡核苷酸的抑制效率高于反义硫代寡核苷酸。相应非修饰反义寡核苷酸较其互补正义链能更有效抑制两种细胞增殖。核苷酸突变明显降低反义硫代寡核苷酸对细胞抑制,并不影响正义硫代寡核苷酸的细胞抑制率。反义硫代寡核苷酸明显降低细胞中bFGF表达。结论硫代修饰bFGF反义寡核苷酸在细胞内特异性结合核酸以反义机制抑制肿瘤细胞增殖,正义寡核苷酸则因硫代修饰于细胞内以非核酸特异性机制抑制肿瘤细胞增殖。     

不同作用靶点的bFGF反义脱氧寡核苷酸对胶质瘤SWO-38细胞效应的观察

目的:比较3条针对不同位点的碱性成纤维细胞生长因子(bFGF)反义脱氧寡核苷酸抑制神经胶质瘤SWO-38细胞bFGF表达的效应。方法:用脂质体介导bFGF反义脱氧寡核苷酸的转染入SWO-38细胞, MTT及流式细胞术检测细胞增殖及凋亡的改变, Western-blot的方法检测bFGF蛋白水平的改变。结果:3条脱氧寡核苷酸链的细胞增殖抑制率分别为49%, 33%, 51%, 促进细胞凋亡率分别为35%、27%、18%, 对bFGF蛋白的表达降低分别为63%、42%、11%。结论:对细胞增殖活力、凋亡率、bFGF蛋白水平均有明显效应的脱氧寡核苷酸序列才是理想的反义物质。     

MMP-7反义寡核苷酸对KATOⅢ细胞MMP-7mRNA表达及其侵袭力的影响

目的:观察MMP-7反义寡核苷酸对恶性肿瘤细胞表达及侵袭的影响,探讨MMP-7在浸润转移中的作用及反义寡核苷酸的治疗意义。方法:将嵌合性硫代磷酸修饰的MMP-7反义寡核苷酸通过FuGENE^TM6导入低分化的胃癌细胞株KATOIII,采用RT-PCR及改良的Boyden-Chamber检测该细胞表达情况及侵袭力。结果:①MMP-7反义寡核苷酸转染的KATOIII细胞MMP-7mRNA表达量(MMP-7/β-actin光密度比值为0.31±0.02)明显低于对照组、PS-sODN及PS-mODN组(分别为1.59±0.01,1.14±0.03,1.51±0.02),P＜0.05。②MMP-7PS-asODN组穿过膜的细胞数明显(15.60±1.21)少于对照组、PS-sODN组及PS-mODN组(分别为75.40±6.16,53.80±7.32,58.40±5.87),P＜0.05。结论:MMP-7反义寡核苷酸可明显降低肿瘤细胞的MMP-7mRNA表达水平和侵袭能力,MMP-7在肿瘤的浸润与转移中起一定的作用。     

反义寡核苷酸抑制神经母细胞瘤LA-N-5细胞血管内皮生长因子mRNA表达及其生物效应的研究

目的研究血管内皮生长因子(VEGF)反义寡核苷酸(ASODN)转染对神经母细胞瘤LA-N-5细胞VEGF mRNA表达的影响以及对肿瘤细胞增殖、分化的影响。方法用LipofectamineTM2000介导的VEGF ASODN和错义寡核苷酸(MSODN)转染LA-N-5细胞,半定量RT-PCR检测各组细胞VEGF165和VEGF121 mRNA转染前后不同时间表达的变化;MTT法测定转染后各组细胞的生长曲线及抑制率。结果半定量RT-PCR检测结果显示,在转染后72 h VEGF165和VEGF121 mRNA的表达:ASODN组为0.346±0.029和0.227±0.036,ASODN+LipofectamineTM2000组为0.275±0.035和0.165±0.017。ASODN组和ASODN+LipofectamineTM2000组均显著抑制VEGF mRNA的表达,ASODN+LipofectamineTM2000组抑制作用较ASODN组更强(P<0.05);转染后ASODN组和ASODN+LipofectamineTM2000组细胞增殖显著受抑,在48 h时抑制率最高,分别为(39.92±2.7...     

bFGF/FGFR信号转导途径与肿瘤

碱性成纤维细胞生长因子（basic fibroblast growth factor, bFGF or FGF-2）是一种对于肿瘤细胞具有促分裂和增殖作用的多肽,其受体(FGFR)是酪氨酸激酶受体家族中的一类, bFGF在多种恶性肿瘤中均有表达,bFGF与FGFR结合以后的信号转导在肿瘤血管形成和肿瘤细胞分裂增殖过程中起重要做用,与肿瘤的发生发展密切相关。     

肿瘤坏死因子α与反义寡脱氧核苷酸联合作用对人胰腺癌细胞生…

目的探讨肿瘤坏死因子α与反义寡脱氧核苷酸的联合应对胰腺癌细胞生长的影响。     

STAT1 ASON对肺纤维化大鼠BALF细胞因子和肺组织Ⅰ、Ⅲ型胶原mRNA表达的影响

目的:观察信号转导子与转录活化子1(STAT1)反义寡核苷酸(ASON)雾化吸入对博莱霉素(BLM)致肺纤维化大鼠肺泡灌洗液(BALF)PDGF-BB(血小板衍生生长因子-BB)、 TNF-α(肿瘤坏死因子-α )、 TGF-β1(转化生长因子-β1)、 IFN-γ(干扰素-γ)表达及肺组织Ⅰ、Ⅲ型胶原mRNA表达的影响.方法:取45只健康雌性Wistar大鼠随机分成ASON组、 BLM组和生理盐水(NS)组各15只, 气管内分别灌注BLM(ASON组、 BLM组)和NS(NS组)复制肺纤维化模型和空白对照, ASON组于第0、 2、 4、 6天雾化吸入STAT1 ASON, BLM组和NS组雾化吸入NS, 各组分别于第7、 14、 28天均处死动物5只.观察肺泡炎和肺纤维化改变;收集BALF测定PDGF-BB、 TNF-α、 IFN-γ、 TGF-β1的水平;测定肺组织Ⅰ、Ⅲ型胶原mRNA表达.结果:ASON组第7、 14、 28天肺泡炎和肺纤维化程度明显低于同时间点BLM组( P <0.05).BLM组各时间点BALF中PDGF-BB、 TNF-α、 TGF-β1表达水平较NS组升高( P <0.05), ASON组较BLM组各时间点均降低( P <0.05);BLM组BALF中IFN-γ表达水平各时间点均低于NS组( P <0.05) , 但ASON组各时间点均较BLM组高( P <0.05).ASON组和BLM组第7、 14、 28天Ⅰ、Ⅲ型胶原mRNA表达高于NS组( P <0.05);ASON组第7、 14、 28天Ⅰ、Ⅲ型胶原mRNA的表达均较同时间点BLM组降低( P <0.05).结论:STAT1 ASON雾化吸入能够减轻BLM诱导的肺泡炎和肺纤维化程度, 其机制可能与抑制BALF中TGF-β1、 PDGF-BB、 TNF-α的表达, 抑制IFN-γ下降而减少肺组织胶原的沉积有关.     

PKC-α、PKA-Ⅰ反义核酸对鼻咽癌CNE-2Z细胞生长增殖的影响

目的 :探讨PKC -α和PKA -Ⅰ反义核酸 (asODN)对鼻咽癌CNE - 2Z细胞生长增殖的影响。方法 :分别用脂质体 (lipofectin ,LP)介导asODN转染鼻咽癌CNE - 2Z细胞。实验组 :① 0 0 1- 1 0 0 μmol/LPKC -αasODN ;②0 0 1- 1 0 0 μmol/LPKA -ⅠasODN ;③ 0 5 0 μmol/LPKC -αasODN +0 5 0 μmol/LPKA -ⅠasODN。对照组 :相应浓度的随机序列 (rODN)。用免疫组化法检测CNE - 2Z细胞PKC -α和PKA -Ⅰ的表达 ,MTT法检测其生长指数 (growthin dex ,GI) ,软琼脂克隆形成率检测其体外增殖能力。结果 :PKC -αasODN或 /和PKA -ⅠasODN均可阻断其相应PKC-α或PKA -Ⅰ的表达 (P <0 0 5 )。PKC -αasODN或PKA -ⅠasODN均能显著降低CNE - 2Z细胞GI和软琼脂克隆形成率 (P <0 0 5 ) ,且具有量效依赖关系。PKC -αasODN +PKA -ⅠasODN共同作用可使其GI和软琼脂克隆形成率非常显著降低 (P <0 0 1) ,无明显量效依赖关系 ,两者对CNE - 2Z生长抑制作用强于PKC -αasODN或PKA -Ⅰa sODN(P <0 0 5 ) ,对其软琼脂克隆形成率的抑制作用与PKC -αasODN或PKA -ⅠasODN无显著差异 (P >0 0 5 )。结论 :PKC -αasODN和PKA -ⅠasODN均可抑制CNE - 2Z细胞体外生长和增殖 ,两者具有协同作用。     

LMP-1 mRNA反义寡核苷酸抑制大鼠成骨细胞的分化

为深入探讨LIM矿化蛋白1（LMP－1）在成骨细胞分化中的作用，体外培养大鼠成骨细胞，在培养基中加入LMP－1反义寡核苷酸（LMP－1antisense终浓度为0．8mol／L），以阻断大鼠成骨细胞中LMP－1mRNA的表达。对照组加nonsense（终浓度为0．8mol／L）。测定细胞的碱性磷酸酶（ALP）活性、培养基中骨钙素（OC）的含量，免疫组化分析Ⅰ型胶原蛋白的表达，Northern blotting检测I型胶原mRAN的表达。结果显示：LMP－1mRNA被LMP－lantisense阻断后，ALP活性降低、OC分泌减少、I型胶原蛋白和mRNA的表达下降。上述结果表明：LMP－1mRNA被LMP－1反义寡核酸阻断后，成骨细胞分化受到明显的抑制，提示LMP－1是成骨细胞分化必不可少的正调节因子。     

Bcl-2硫代反义寡核苷酸对人恶性黑色素瘤A375细胞增殖和凋亡的影响

目的:研究bcl-2硫代反义寡核苷酸(bcl-2ASODN)对人恶性黑色素瘤细胞A375增殖和凋亡的影响及其作用机制。方法:采用MTT法、激光共聚焦显微镜、TUNEL法和AnnevinV/PI双染法检测bcl-2ASODN对A375细胞增殖和凋亡的影响。应用RT-PCR方法,观察bcl-2ASODN处理前后bcl-2mRNA在A375细胞表达水平的变化。结果:MTT法检测显示bcl-2ASODN抑制A375细胞增殖,并呈时间和剂量依赖性;经30μmol/LASODN作用48h,激光共聚焦显微镜观察细胞呈现典型凋亡特征;TUNEL染色可见ASODN组多数A375细胞核被标记呈棕褐色,而SODN组和对照组细胞核未被明显标记;AnnexinV/PI检测ASODN组凋亡细胞比例升高,与SODN组和对照组均有显著性差异(P<0.001);RT-PCR结果显示bcl-2mRNA表达水平下降。结论:bcl-2ASODN可抑制A375细胞增殖和诱导A375细胞凋亡,其诱导凋亡的机制是下调bcl-2mRNA的表达。     

Expression and localization of FGFR1, FGFR2 and CTGF during normal human lung development

Aim of our study was to provide insight into the temporal and spatial expression of FGFR1, FGFR2 and CTGF during normal human lung development which may have an important impact on understanding occurrence of developmental lung anomalies. Morphological parameters were analysed using double immunofluorescence on human embryonal (6th and 7th developmental week-dw) and foetal (8th, 9th and 16th developmental week) human lung samples.FGFR1 and FGFR2 was positive during all the dw in both the epithelium and mesenchyme. The highest number of FGFR1 positive cells was observed during the 6th dw (112/mm²) and 9th dw (87/mm²) in the epithelium compared to the 7th, 8th and 16th dw (Kruskal-Wallis test, p < 0.001, p < 0.0001). The highest number of FGFR1 positive cells in the mesenchyme was observed during the 8th dw (19/mm²) and 16th dw (13/mm²) compared to the 6th, 7th, and 9th dw (Kruskal-Wallis test, p < 0.001, p < 0.0001). The number of FGFR1 positive cells in the epithelium was higher for FGFR2 compared to number of positive cells (Mann-Whitney test, p < 0.0001). FGFR2 showed the highest number in the epithelium during the 7th dw (111/mm²) and 9th dw (87/mm²) compared to 6th, 8th and 16th dw (Kruskal-Wallis test, p < 0.001, p < 0.0001, p < 0.01 respectively). The highest number of FGFR2 positive cells in the mesenchyme was observed during the 9th dw (26/mm²), compared to the 6th, 7th,8th and 16th dw (Kruskal-Wallis test, p < 0.0001), while the number of FGFR2 positive cells in the epithelium was significantly higher than in the mesenchyme (Mann-Whitney test, p < 0.0001). CTGF was negative in both epithelium and mesenchyme during all except the 16th dw in the mesenchyme where it co-localized with FGFR2.FGFR1 and FGFR2 might be essential for epithelial-mesenchymal interactions that determine epithelial branching and mesenchymal growth during early lung development. Sudden increase in FGF1 in the epithelium and FGF2 in the mesenchyme in the foetus at 9th dw could be associated with the onset of foetal breathing movements. CTGF first appear during the foetal lung development.     

Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses

Dominant mutations in three fibroblast growth factor receptor genes (FGFRs1-3) cause Crouzon, Jackson-Weiss, Pfeiffer, and Apert syndromes. In the present study, 50 Brazilian patients with these four syndromes (27 Apert, 17 Crouzon, 5 Pfeiffer, and 1 Jackson-Weiss patients) were screened for mutations in the FGFR1-3 genes. Except for one, all the Apert patients had either S252W (n = 16) or P253R (n = 10) mutations. The remaining Apert case is atypical with a mutation altering the splice site of FGFR2 exon IIIc. The Pfeiffer patients had mutations in one of the FGFR genes: three in FGFR2, one in FGFR1, and one in FGFR3. In contrast, only 8 of the 17 Crouzon patients studied had a mutation in either FGFR2 (n = 7) or FGFR3 locus (n = 1). Mutations in the FGFR2 locus account for most (93%) of our syndromic craniosynostotic cases, whereas 5% had mutations in the FGFR3 locus and only 2% had mutations in the FGFR1 gene. Except for one, all the other mutations were reported previously in craniosynostotic patients from other populations. Interestingly, the mutation C278F, previously described in Crouzon and Pfeiffer cases, was here identified in a familial case with Jackson-Weiss. Also, unexpectedly, a common mutation altering the splice site of the FGFR2 exon IIIc was found in one Apert and two Pfeiffer patients. In addition, we identified a new mutation (A337P) in the FGFR2 exon IIIc associated with Crouzon phenotype. Am. J. Med. Genet. 78:237–241, 1998. © 1998 Wiley-Liss, Inc.     

非小细胞肺癌中Notch1、HIF-1、VEGF蛋白及Notch1 mRNA的表达及意义

目的 探讨Notch1、HIF-1、VEGF蛋白及Notch1 mRNA在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织的表达及其临床病理学意义.方法 采用免疫组化SP法和原位杂交法分别检测65例NSCLC组织、15例正常支气管上皮组织中Notch1、HIF-1、VEGF蛋白及Notch1 mRNA的表达.结果 Notch1、HIF-1、VEGF蛋白及Notch1 mRNA在非小细胞肺癌中阳性表达率分别为81.5%(53/65)、96.9%(63/65)、93.8%(61/65)、73.8%(48/65),均明显高于正常支气管上皮组织阳性表达率(P<0.05);NSCLC中Notch1、HIF-1、VEGF蛋白及Notch1 mRNA的表达均与临床分期、淋巴结转移有关(P<0.05);Notch1、HIF-1与VEGF蛋白间均正相关;Notch1蛋白与Notch1 mRNA的表达呈正相关.结论Notch1、HIF-1、VEGF蛋白及Notch1 mRNA在NSCLC中均表达上调,提示在肺癌的发生、发展中可能起重要作用;检测NSCLC组织Notch1蛋白及mRNA可作为判断肿瘤侵袭与转移的重要指标.     

bFGF enhances the IGFs-mediated pluripotent and differentiation potentials in multipotent stem cells

It has widely been reported that basic fibroblast growth factor (bFGF) promotes proliferation of human stem cells and contributes to the maintenance of their self-renewal capability through repeated replications. In contrast to embryonic stem cells (ESCs), the effects of growth factors on adult stem cells are poorly understood.

In human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs), bFGF is associated with an increased number of proliferating cells. Furthermore, expression levels of ESC markers were increased after treatment with bFGF. bFGF also increased the expression of FGFR, which in turn increased expression of insulin-like growth factor (IGFs). Since IGFs exert autocrine and paracrine effects on stem cells, bFGF-mediated release of IGFs from hUCB-MSCs might enhance FGFR1 and IGF1R expression in neighboring cells. These receptors could subsequently regulate the effects of bFGF and IGFs in adult stem cells.

These results suggest that positive feedback regulation of bFGF and IGFs leads to proliferation of hUCB-MSCs.     

Immunohistochemical expression pattern of RIP5, FGFR1, FGFR2 and HIP2 in the normal human kidney development

AimPresent study analyses the co-localisation of RIP5 with FGFR1, FGFR2 and HIP2 in the developing kidney, as RIP5 is a major determinant of urinary tract development, downstream of FGF-signaling.MethodsParaffin embedded human kidney tissues of 16 conceptuses between the 6th-22th developmental week were analysed using double-immunofluorescence method with RIP5/FGFR1/FGFR2 and HIP2 markers. Quantification of positive cells were performed using Kruskal–Wallis test.ResultsIn the 6th week of kidney development RIP5 (89.6%) and HIP2 (39.6%) are strongly expressed in the metanephric mesenchyme. FGFR1 shows moderate/strong expression in the developing nephrons (87.3%) and collecting ducts (70.5%) (p < 0.05). RIP5/FGFR1 co-localized at the marginal zone and the ureteric bud with predominant FGFR1 expression. FGFR2 (26.1%) shows similar expression pattern as FGFR1 (70.5%) in the same kidney structures. RIP5/FGFR2 co-localized at the marginal zone and the collecting ducts (predominant expression of FGFR2). HIP2 is strongly expressed in collecting ducts (96.7%), and co-localized with RIP5. In 10th week, RIP5 expression decrease (74.2%), while the pattern of expression of RIP5 and FGFR1 in collecting ducts (33.4% and 91.9%) and developing nephrons (21.9% and 32.4%) (p < 0.05) is similar to that in the 6th developmental week. Ureter is moderately expressing RIP5 while FGFR1 is strongly expressed in the ureteric wall. FGFR2 is strongly expressed in the collecting ducts (84.3%) and ureter. HIP2 have 81.1% positive cells in the collecting duct. RIP5/FGFR1 co-localize in collecting ducts and Henley’s loop.ConclusionsThe expression pattern of RIP5, FGFR1, FGFR2 and HIP2 in the human kidney development might indicate their important roles in metanephric development and ureteric muscle layer differentiation through FGF signaling pathways.     

NCAM and FGFR1 coexpression and colocalization in renal tumors

Neural cell adhesion molecule (NCAM) and fibroblast growth factor receptor (FGFR) have a role in epithelial-mesenchymal transformation during tumor genesis. Interplay between both molecules activates FGFR signaling and it could be responsible for tumor development. Renal epithelial tumors were analyzed for FGFR1 and NCAM coexpression by immunohistochemistry and for colocalization of these molecules on the particular tumor cells by triple immunofluorescence. Detection of NCAM isoforms in renal tumors was evaluated by RT-PCR. Applying immunohistochemistry we revealed that the majority of analyzed renal neoplasms, including renal cell carcinoma (RCC) and oncocytoma coexpressed NCAM and FGFR1. Triple immunofluorescent technique confirmed that both markers are commonly colocalized on the same tumor cells. Interestingly, it seemed that different position of NCAM and FGFR1 expression on renal tumor cells is related to renal tumor type or grade: exclusively membranous FGFR1/NCAM expression occurred in low grade clear cell RCC (cRCC); cytoplasmatic and membranous expression was present in high grade cRCC and other RCC types; oncocytoma showed only cytoplasmatic staining of both markers. NCAM-140 and NCAM-120 were detected in almost all analyzed renal neoplasms. Expression of both molecules on different cell compartments in various kidney tumors indicated that NCAM/FGFR1 interaction could play distinct roles in renal tumor genesis.